Equine Serum Used In COVID-19 Clinical Trials

People affected by COVID-19 in Argentina may become part of clinical trials using a new, hyperimmune solution utilizing equine serum. The serum was developed by biotech company Inmunova in conjunction with San Martín University.

The trials will take place in four hospitals, as well as in 10 health centers around Buenos Aires, where 90 percent of the country’s coronavirus cases have occurred.

The treatment delivers antibodies to the affected people; it is hoped that these antibodies will be able to stop the virus, as well as prevent the disease from developing. The serum is based on equine polyclonal antibodies, which occur after the horse is injected with recombinant protein of SARS-CoV-2.

Unaffected by the disease, the horse’s body generates large quantities of antibodies. Blood is drawn from the horse and plasma extracted; the antibodies are then purified and processed. Used in humans, it is expected that the antibodies will be able to prevent the virus from entering cells, where they then multiply.

Read more at the Buenos Aires Times.

The post Equine Serum Used In COVID-19 Clinical Trials appeared first on Horse Racing News | Paulick Report.

DYFD Winter - 300x90

Comments are closed.